Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 26 | 26 | 7 |
Full Text Views | 297 | 103 | 1 |
PDF Downloads | 63 | 18 | 0 |
Clinical trials to evaluate schistosomal vaccines are in progress. We discuss the desired characteristics of such a vaccine, propose a product profile, and consider the clinical and pre-clinical studies needed for its licensure, within practical and ethical constraints. We believe that licensure of a schistosomal vaccine will be greatly facilitated by resolution of the following issues: identification of the human immunoprotective antigens and mechanisms; induction of the appropriate responses by adjuvanted vaccines; understanding the effect of immunization on immunopathology; development of an improved serologic assay to determine worm burden; generation of approximately $500 million to fund the project; and development of a physical infrastructure with trained professionals in disease-endemic countries to perform Phase III clinical trials. We also believe that development of a schistosomal vaccine, while a long range goal, is possible and desirable, and we have indicated some of the practical steps that will be required to achieve this laudable accomplishment.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 26 | 26 | 7 |
Full Text Views | 297 | 103 | 1 |
PDF Downloads | 63 | 18 | 0 |